18F-氟胆碱PET/CT对原发性甲状旁腺功能亢进症功能亢进甲状旁腺组织定位的敏感性优于11C-蛋氨酸PET/CT
本研究纳入58例生化证实原发性甲状旁腺功能亢进症且99mTc-MIBI SPECT阴性或不确定的患者,比较18F-FCH与11C-MET PET/CT定位功能亢进甲状旁腺组织的诊断效能。结论认为在99mTc-MIBI SPECT阴性或不确定时,18F-FCH PET/CT能更好地定位病理甲状旁腺组织。
要点
- 18F-FCH PET/CT患者水平敏感性96%、阳性预测值96%,显著高于11C-MET的60%和94%。
- 18F-FCH PET/CT病灶水平敏感性84%、阳性预测值90%,显著高于11C-MET的52%和94%。
- 在99mTc-MIBI SPECT阴性或不确定的pHPT患者中,18F-FCH PET/CT可定位96%患者的甲状旁腺腺瘤或增生。
核心结论
- 在生化证实原发性甲状旁腺功能亢进症且99mTc-MIBI SPECT阴性或不确定的患者中,18F-FCH PET/CT对病理甲状旁腺组织的检测效能优于11C-MET PET/CT,可在96%的患者中定位甲状旁腺腺瘤或增生。
研究设计与样本
- PET/CT结果根据结节样示踪剂摄取及CT对应结节显示分为阳性、不确定或阴性三类,并与手术及组织病理学结果(金标准)进行相关性分析。
主要发现
- 18F-FCH PET/CT阳性39例(74%)、不确定5例(9%)、阴性9例(17%);11C-MET PET/CT分别为25例(47%)、12例(23%)、16例(30%)。
- 与11C-MET相比,18F-FCH额外定位11个病灶(6个阳性、5个不确定)。
- 26例患者接受手术,切除31个病灶(22个腺瘤、6个增生腺体、3个癌)和1个正常腺体;术后随访21例(81%)治愈,3例(12%)持续高钙血症。
- 将不确定病例视为阴性时,18F-FCH PET/CT在26例患者中的24例(92%)正确 localization 26个病灶,11C-MET PET/CT在26例中的15例(58%)定位16个病灶。
- 患者水平敏感性和阳性预测值:18F-FCH为96%和96%,11C-MET为60%和94%(P<0.0001);病灶水平敏感性和阳性预测值:18F-FCH为84%和90%,11C-MET为52%和94%(P<0.0001)。
临床怎么用
- 对于生化证实pHPT但99mTc-MIBI SPECT阴性或不确定的患者,可优先考虑使用18F-FCH PET/CT进行术前定位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preoperative molecular imaging is paramount to direct surgery in primary hyperparathyroidism (pHPT). We investigated the diagnostic performance of 18F-fluorocholine (18F-FCH) PET/CT compared with 11C-methionine (11C-MET) PET/CT for localization of hyperfunctioning parathyroid tissue in patients with pHPT and negative or inconclusive 99mTc-sestaMIBI (99mTc-MIBI) SPECT findings. Methods: Fifty-eight patients with biochemical evidence of pHPT and negative or inconclusive 99mTc-MIBI SPECT findings were referred for presurgical detection and localization of hyperfunctioning parathyroid tissue by 11C-MET and 18F-FCH PET/CT. The PET/CT results were classified into 3 categories (positive, inconclusive, or negative) based on the nodular aspect of tracer uptake and the visualization of corresponding nodules on CT. The PET/CT results were correlated with the surgical and histopathologic findings, which were used as the gold standard. Results: Fifty-three patients were included for analysis. 18F-FCH PET/CT was positive in 39 patients (74%), inconclusive in 5 (9%), and negative in 9 (17%), compared with 25 (47%), 12 (23%), and 16 (30%), respectively, for 11C-MET PET/CT. 18F-FCH localized 11 additional foci (6 positive and 5 inconclusive), compared with 11C-MET. Twenty-six patients (sex ratio, 10/16 M/F) underwent surgery, with resection of 31 lesions (22 adenomas, 6 hyperplastic glands, and 3 carcinomas) and 1 normal gland. At follow-up, 21 patients (81%) were considered cured after surgery, whereas 3 patients (12%) had persistence of hypercalcemia. With inconclusive cases being considered negative, 18F-FCH PET/CT correctly localized 26 lesions in 24 of 26 patients (92%), compared with 16 lesions in 15 of 26 patients (58%) localized by 11C-MET PET/CT. Per-patient-based sensitivity and positive predictive value were 96% and 96%, respectively, for 18F-FCH and 60% and 94%, respectively, for 11C-MET (P < 0.0001). Per-lesion-based sensitivity and positive predictive value were 84% and 90%, respectively, for 18F-FCH and 52% and 94%, respectively, for 11C-MET (P < 0.0001). Conclusion: In the presence of biochemical evidence of pHPT with negative or inconclusive 99mTc-MIBI SPECT findings, 18F-FCH PET/CT performs better than 11C-MET PET/CT for the detection of pathologic parathyroid tissue, allowing localization of parathyroid adenoma or hyperplasia in 96% of patients.
引用
- Mathey C, Keyzer C, Blocklet D, et al. 18F-Fluorocholine PET/CT Is More Sensitive Than 11C-Methionine PET/CT for the Localization of Hyperfunctioning Parathyroid Tissue in Primary Hyperparathyroidism. J Nucl Med. 2021. PMID: 34413141. doi:10.2967/jnumed.121.262395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。